Some HDL-raising pharmacological compounds have been considered as potential therapies for COVID-19, such as cholesteryl ester transfer protein (CETP)-inhibitors, recombinant cholesterol acyltransferase (LCAT) [40]. Here, LCAT is linked to COVID-19.